Commercial-stage customers push Cryoport's quarterly sales up 14%, prompting higher annual forecast
The cell and gene therapy logistics specialist reported $50.2 million in third-quarter sales and raised its full-year expectations, while still recording a net loss of $10.9 million.
Cryoport says its customers with approved cell and gene therapies were the main engine of third-quarter growth. Revenue from that commercial group rose 20%, helping lift total sales 14% to $50.2 million, the company reported on 5 November.
Profitability was mixed. Cryoport booked a net loss of $10.9 million for the period, but adjusted EBITDA was positive at $1.1 million. The summary available does not set out the adjustments between the two measures.
On the back of the quarter, the company raised its 2026 sales guidance to between $197 million and $199 million. The earlier range was not included in the information available, so the size of the increase cannot be stated.
Cryoport also gave a snapshot of its customer base: it now supports 23 commercial therapies and a record 788 clinical trials. No detail was provided on regional performance or on the programmes behind these figures.
Why it matters
- Faster growth from commercial-stage customers than from the business overall suggests approved therapies are becoming a larger share of demand for specialist logistics (company-reported, one quarter only).
- A positive adjusted EBITDA alongside a $10.9 million net loss shows the business is not yet profitable on a reported basis.
- The raised guidance range signals management confidence, but the prior range is not disclosed, so the scale of the upgrade is unclear.
Company's press release (SEC filing): Cryoport, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
